NASDAQ$TSHA
Taysha Gene Therapies Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Taysha Gene Therapies reported financial results for Q2 2023, with a net loss of $24.6 million, or $0.38 per share. The company's cash and cash equivalents totaled $45.1 million as of June 30, 2023. A private placement financing is expected to result in gross proceeds of approximately $150 million, extending the cash runway into the third quarter of 2025.
- Initial data from the first adult patient dosed in the REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated and demonstrated improvement in key efficacy measures.
- The FDA cleared the IND application for TSHA-102 in pediatric patients with Rett syndrome.
- A CTA was submitted to the U.K. MHRA for TSHA-102 in pediatric patients with Rett syndrome.
- A private placement financing is expected to result in gross proceeds of approximately $150 million, extending cash runway into the third quarter of 2025.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$2.4M
Forward guidance
Net proceeds from PIPE, along with existing cash and cash equivalents, extends cash runway into the third quarter of 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro